Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling

High-attrition rates during clinical development of new cancer therapies still persist. A new 3D ex vivo microfluidics platform shall now enhance cancer drug screening and early development process by creating cancer models which predict clinical outcomes with significantly increased reliability.

Read the full article